Pérez-Ruiz, ElisabethEtxeberria, IñakiRodriguez-Ruiz, Maria EMelero, Ignacio2025-01-072025-01-072017-08-08https://hdl.handle.net/10668/26705T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.enAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenClinical Trials, Phase I as TopicDrug SynergismHumansMolecular Targeted TherapyNeoplasmsProgrammed Cell Death 1 ReceptorTreatment OutcomeTumor Necrosis Factor Receptor Superfamily, Member 9research article2879011810.1158/1078-0432.CCR-17-17991557-3265